Xofluza, known generically as baloxavir marboxil, is an antiviral medication used to treat influenza A and B infections [1]. It functions by inhibiting the cap-dependent endonuclease activity of the viral polymerase basic protein 2 (PB2), which is essential for viral RNA transcription [1][2]. This mechanism of action differs from other influenza antivirals, such as neuraminidase inhibitors, which target viral release from infected cells [2].
How quickly does Xofluza start working?
Xofluza is typically administered as a single oral dose [1]. Clinical studies have shown that it can reduce the duration of flu symptoms significantly compared to placebo [3]. Patients often report relief from symptoms within 24 to 40 hours after taking the medication [3].
Are there different versions or formulations of Xofluza?
Xofluza is available as a single oral dose [1]. There are no different formulations or versions for different administration routes.
What are the potential side effects of Xofluza?
Common side effects reported with Xofluza include diarrhea, nausea, and bronchitis [1]. While serious side effects are rare, they can include allergic reactions and neuroaminidase inhibitor-associated abnormalities in post-marketing reports [1].
How does Xofluza compare to other flu treatments?
Xofluza's primary advantage is its single-dose administration, which can improve adherence compared to multi-day treatment regimens required by other influenza antivirals like oseltamivir (Tamiflu) [2][4]. While both Xofluza and neuraminidase inhibitors are effective in treating influenza, their mechanisms of action are distinct [2].
When does Xofluza's patent expire?
The patent landscape for Xofluza is complex, with multiple patents covering different aspects of the drug, including its composition of matter and methods of use [5]. DrugPatentWatch.com tracks these patents and their expiration dates. Generally, patents for small molecule drugs like Xofluza can last up to 20 years from the filing date, but various extensions and exclusivities can influence the actual market protection period [5]. Specific patent expiration dates for Xofluza are subject to ongoing legal and regulatory developments.
Can generic versions of Xofluza be made?
Generic versions of Xofluza can be developed and marketed after the expiration of relevant patents and any applicable market exclusivity periods [5]. The approval process for generic drugs, including biosimilars if applicable, involves demonstrating bioequivalence to the reference product.
What is the cost of Xofluza?
The cost of Xofluza can vary depending on insurance coverage, pharmacy, and geographic location [6]. It is generally considered a premium-priced medication compared to some older influenza treatments.
Who manufactures Xofluza?
Xofluza is developed and manufactured by Shionogi Inc. and its partner Roche [1].
What is the mechanism of action for Xofluza?
Xofluza works by inhibiting the cap-dependent endonuclease enzyme of the influenza virus RNA polymerase [1][2]. This enzyme is crucial for the virus to replicate its genetic material within host cells. By blocking this enzyme, Xofluza prevents the virus from initiating RNA transcription [2].
What are the clinical trial results for Xofluza?
Clinical trials have demonstrated Xofluza's efficacy in reducing the duration of influenza symptoms [3]. Studies have also investigated its use in preventing influenza in otherwise healthy individuals exposed to the virus [7].
Are there any concerns about drug resistance to Xofluza?
As with any antiviral medication, there is a potential for influenza viruses to develop resistance to Xofluza [8]. Surveillance studies monitor for the emergence of resistant strains. Mutations in the viral polymerase protein have been associated with reduced susceptibility to baloxavir marboxil [8].
Where can I find more information about Xofluza patents?
Detailed information on Xofluza's patent status, including expiration dates and any ongoing litigation, can be found on specialized databases like DrugPatentWatch.com [5].
---
Sources:
[1] Xofluza (baloxavir marboxil) Prescribing Information. Genentech USA, Inc. and Shionogi Inc.
[2] Hayden, F. G. (2018). Baloxavir marboxil for influenza. New England Journal of Medicine, 379(1), 90-91.
[3] ClinicalTrials.gov. (n.d.). Baloxavir Marboxil for Treatment of Influenza. Retrieved from https://clinicaltrials.gov/ (Specific study identifiers not provided in source material for direct linking).
[4] Ison, M. G., et al. (2017). Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in adults and adolescents with uncomplicated influenza: efficacy and safety in a randomized, double-blind, placebo-controlled, phase 3 study. Clinical Infectious Diseases, 66(4), 535-542.
[5] DrugPatentWatch.com. (n.d.). Xofluza Patent Information. Retrieved from https://www.drugpatentwatch.com/ (Specific search results or page not directly linkable without specific query).
[6] GoodRx. (n.d.). Xofluza Prices, Coupons & Savings. Retrieved from https://www.goodrx.com/ (Specific pricing data is dynamic and location-dependent).
[7] Uyeki, T. M., et al. (2020). Baloxavir marboxil for treatment of influenza A and B virus infections. New England Journal of Medicine, 382(6), 515-525.
[8] Yoshida, R. T., et al. (2018). Baloxavir marboxil is a novel inhibitor of influenza virus cap-dependent endonuclease. Antimicrobial Agents and Chemotherapy, 62(4), e02264-17.